CD Biosciences Inc.
Shirley, NY Doing business as Creative Biomart Creative Biomart, Creative Biolabs, CD Genomics, Profacgen
- UEI
- YZSQGQE8DJ55
- CAGE
- 63BC3
- SAM.gov registration
- Active through
Company facts
- FY2025 rankings
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- Other NAICS codes in SAM.gov
-
- 325199 All Other Basic Organic Chemical Manufacturing
- 325411 Medicinal and Botanical Manufacturing
- 325413 In-Vitro Diagnostic Substance Manufacturing
- 325414 Biological Product (except Diagnostic) Manufacturing
- 334516 Analytical Laboratory Instrument Manufacturing
- 541380 Testing Laboratories and Services
- 541690 Other Scientific and Technical Consulting Services
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Show all 9
- SAM.gov registration date
- Physical address
- 45 Ramsey Rd #16, Shirley, NY 11967, USA
- Website
- cd-biosciences.com
- Employees
- 1-10
- Estimated annual revenue
- $0-$1M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $50,342 |
| FY2025 | $51,300 |
| FY2024 | $81,380 |
| FY2023 | $173,938 |
Top agencies by obligations
| Rank | Agency | Obligated, FY2026–FY2027 | Share |
|---|---|---|---|
| 1 | Department of Agriculture | $63,560 | |
| 2 | Department of Veterans Affairs | $41,106 |
Contract awards
Latest 5 listed here. See the rest on GovTribe.
Similar vendors
About the company
CD Biosciences Inc., doing business as Creative Biomart, Creative Biolabs, CD Genomics, and Profacgen Division, is a small business contract research organization headquartered in East Yaphank, New York, that provides genomic sequencing, bioinformatics analysis, and molecular biology services to federal agencies as a prime contractor under small business set-asides and full-and-open competition. The company competes under Total Small Business designations on roughly half its recent awards, with the remainder awarded on unrestricted full-and-open basis.
CD Biosciences' capability portfolio centers on next-generation DNA and RNA sequencing, TCR (T-cell receptor) sequencing, metagenomic and genotyping services, and specialized molecular diagnostics. Representative work includes a $63,560 phage library screening purchase order from the Department of Agriculture's Agricultural Research Service (August 2026) for peptide sequence identification at the National Bio and Agro-Defense Facility in Manhattan, Kansas; a $109,730 single-award indefinite-delivery contract with USDA-ARS (June 2022–June 2024) for genome survey sequencing, mRNA-seq transcriptomic sequencing, amplicon-based metagenomic sequencing, and bioinformatic analyses across up to 146 samples; and $40,406 and $45,200 delivery orders under a $180,700 ceiling indefinite-delivery contract with Veterans Integrated Service Network 22 for TCR sequencing services with performance in Loma Linda, California and Tucson, Arizona through September 2027.
Customer concentration splits across federal research and health agencies. The top five funders by award count account for 58% of recent awards, led by the National Institute of Allergy and Infectious Diseases (13 awards, $378 thousand combined potential value) and the Food and Drug Administration (10 awards, $310 thousand), followed by USDA-ARS regional offices (Pacific West, Northeast, and Plains areas combined, 12 awards, $180 thousand). When ranked by potential value, the Department of the Navy Bureau of Medicine and Surgery ($640 thousand across 2 awards) anchors the portfolio, followed by NIAID and FDA. The company serves 22 distinct customer agencies with a combined portfolio of $2.1 million potential value across 60 prime awards; roughly 59% of potential value is obligated. Activity has declined year over year — six awards in 2022 to one award in 2026 — with only one award ($45 thousand) reaching completion within the next twenty-four months. CD Biosciences places work under two named indefinite-delivery contracts: the USDA-ARS IDC (36C26225D0121, 2 task orders, $86 thousand combined value) and a Department of the Navy contract (N6264518D5069, 1 task order, $40 thousand). Work is performed at the contractor's East Yaphank facility and at agency research sites including NBAF Manhattan, Kansas; VA medical centers in Tucson and Loma Linda; and NIAID and CDC laboratories. The vendor holds no subcontract relationships in the source data — all 60 awards are prime awards.
Quick answers
Is CD Biosciences Inc. registered in SAM.gov?
Yes. CD Biosciences Inc.'s SAM.gov registration is active through July 22, 2027.
How much has CD Biosciences Inc. received in federal contracts?
Federal contracts obligated $51,300 to CD Biosciences Inc. in fiscal year 2025 and $356,960 in fiscal years 2023 through 2027.
How does CD Biosciences Inc. rank among federal contractors?
CD Biosciences Inc. ranked #96 in PSC AN13 in FY2025.
What is CD Biosciences Inc.'s most recent federal award?
CD Biosciences Inc.'s most recent federal contract award is Phage library screening, national BIO and agro-defense facility, manhattan, kansas (1232SA26P0458), from Central Program Planning Coordination and Support (ARS), on August 2, 2026.
On GovTribe
See CD Biosciences Inc.'s full federal record
- Federal contract awards
- IDV awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors